The COG SDC is responsible for all statistical and data operations within the COG. It also supports many of the administrative activities of the COG. The IT support required for all statistical and data center operations is also provided by the SDC grant.
The specific aims of the SDC are to: 1. Collaborate on the development of the COG's scientific agenda, as full members of Disease and Modality Committees 2. Provide leadership in the design of COG research, collaborating on the development of study pre-concepts, concepts, and protocols and providing study statistical considerations, includingsample size calculations and interim monitoringplans 3. Collaborate on the development of study case report forms used to collect the minimal data required for the evaluation of the study aims 4. Maintain a centralized remote data entry system to collect study data from COG institutions,resource centers, and reference laboratories, and maintainquality control procedures to assure the accuracy of COG research data 5. Monitor study data submitted by participating COG institutions,monitor the timeliness of data submissionand provide institutionswith expectancy and delinquencyreports, review submitted data, coordinate the collection and review of materials collected for modality reviews (pathology, surgery, radiation therapy), and coordinate study committee review of study data 6. Monitor study conduct, includingaccrual, patient safety, and study outcome;prepare public protocol progress reports for the COG and confidential reports of interim outcome data for the COG's Data Monitoring Committees 7. Collaborate on the production of abstracts and manuscripts reporting the results of COG science 8. Conduct research on statistical methods that have direct relevance to COG's research goals and conduct special analyses (e.g., on prognostic factors, outcome for specific patient subsets, etc.), taking advantage of the wealth of information contained in the group's research databases 9. Provide statistical collaboration for the COG's correlative laboratory research agenda. 10. Collaborate with members of the Group Operations Center in the completion of various administrative activities, including institutional audits and institutional performance monitoring 11. Provide education and training to the Group membership, including collaboration on the trainingof new study chairs, collaboration on new and continuingeducation training for institutionalclinical research associates and presentations on statistical issues of interest to the Group membership.
|Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892|
|Voigt, Andrew P; Brodersen, Lisa Eidenschink; Alonzo, Todd A et al. (2017) Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. Haematologica 102:2058-2068|
|Lee, Sanghoon; Day, Nancy S; Miles, Rodney R et al. (2017) Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 177:601-611|
|Hardy, Kristina K; Embry, Leanne; Kairalla, John A et al. (2017) Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. J Clin Oncol 35:2700-2707|
|Lim, Emilia L; Trinh, Diane L; Ries, Rhonda E et al. (2017) MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. J Clin Oncol 35:3964-3977|
|Ermoian, Ralph P; Breneman, John; Walterhouse, David O et al. (2017) 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 64:|
|Liu, C; Yang, W; Pei, D et al. (2017) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther 101:373-381|
|Tasian, Sarah K; Teachey, David T; Li, Yong et al. (2017) Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129:177-187|
|Esbenshade, Adam J; Kocak, Mehmet; Hershon, Linda et al. (2017) A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Gro Pediatr Blood Cancer 64:|
|Taub, Jeffrey W; Berman, Jason N; Hitzler, Johann K et al. (2017) Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood 129:3304-3313|
Showing the most recent 10 out of 438 publications